Document is current
Any future updates will be listed below
-
Authors
Di Pastena, Fiorella
Pond, Gregory
Tsakiridis, Evangelia E.
Gouveia, Andre
Ahmadi, Elham
Biziotis, Olga-Demetra
Ali, Amr
Swaminath, Anand
Okawara, Gordon
Ellis, Peter M.
Abdulkarim, Bassam
Ahmed, Naseer
Robinson, Andrew
Roa, Wilson
Valdes, Mario
Kavsak, Peter
Wierzbicki, Marcin
Wright, James
Steinberg, Gregory
Tsakiridis, Theodoros
-
Funding
Funding for this research was provided by:
Canadian Institutes for Health Research (0000)
Canadian Institutes for Health Research (0000)
Hamilton Health Sciences Foundation (0000)
- License Information
-
More Information
Article History
Received: 14 April 2024
Accepted: 23 October 2024
First Online: 7 November 2024
Declarations
:
: The clinical trial protocol of OCOG-ALMERA including the section of biospecimen collection and corresponding consent forms, received Health Ethics approval from all institutional and provincial ethics boards of participating institutions. This included the Ontario Cancer Research Ethics Board (OCREB), McGill University Research Ethics Board (REB), University of Manitoba REB and Health Research Ethics Board of Alberta (HREBA). Laboratory analysis was conducted with approval by the Hamilton integrated Research Ethics Board (HiREB) (#17511).
: All patients willing to provide biospecimen signed the ethics board approved informed-consent forms before donating their biospecimen. This consent form clearly stated that biospecimen will be collected, shipped to Juravinski Cancer Centre, Hamilton, Ontario, and will be used for the purpose of biomarker analysis, in combination with clinical data, in an anonymized fashion.
: The authors declare no competing interests.
